Stakeholders in the pharmaceutical industry are currently exploring the implementation of artificial intelligence (AI) based tools to expedite drug discovery timelines, minimize attrition rates of candidates and reduce capital investments
Roots Analysis has announced the addition of “AI-based Drug Discovery Market, 2022 - 2035” report to its list of offerings.
The use of AI-based tools in drug discovery operations is likely to not only improve overall R&D productivity, but also reduce clinical failure with accurate predictions of a drug candidate’s safety and efficacy during the early stages of drug development. As the adoption of AI and machine learning increases amongst innovators in the pharmaceutical industry, lucrative opportunities are expected to be created for players engaged in the AI-based drug discovery market.
To order this 335+ page report, which features 155+ figures and 205+ tables, please visit
https://www.rootsanalysis.com/reports/ai-based-drug-discovery-market.html
Over 205 companies claim to offer AI-based drug discovery services / technologies
Majority of the firms (80%) engaged in this domain are small players, followed by mid-sized companies (15%) and large or very large firms (5%). Additionally, more than 50% of the stakeholders were established post 2015. Further, 54% of the players are based in North America; within this region, the US emerged as the most prominent hub, featuring the presence of the maximum number of players.
Around 45 companies offer AI-based drug discovery services / technologies for all three steps of drug discovery
Majority (91%) of the players engaged in AI-based drug discovery market claim to have required expertise in lead identification / optimization / generation. Over 55 stakeholders claim to offer AI-based drug discovery services for both small molecules and biologics.
Partnership activity within this domain has grown at a CAGR of 50%, between 2015 and 2021
Over 375 agreements have been inked in the last 5 years; 65% of the deals were focused on research and development. Other popular types of partnership models adopted by players engaged in this domain include technology access / utilization (10%) and acquisitions (4%).
~11 USD billion has been invested by both private and public investors in this domain, since 2006
Specifically, in 2021, industry players raised over USD 4.7 billion. In addition, majority of the companies (66%) primarily received funding through venture capital rounds. Further, around 60% of the total funding instances were reported by players headquartered in the US.
250+ patents related to AI-based drug discovery have been granted / filed between 2019 and 2022
R&D activity related to AI-based drug discovery is largely concentrated in North America, considering the fact that 48% of the total number of patents were filed in this region. In addition, most of the patents in this domain are patent applications (91%), followed by granted patents (7%).
An elaborate valuation analysis of companies that are engaged in providing AI-based drug discovery services / technologies
We have prepared a proprietary, multi-variable dependent valuation model to estimate the current valuation of a number of companies focused on deploying AI-based technologies in the drug discovery and development operations.
Use of AI-based solutions in drug discovery has demonstrated the ability to enable up to 25% cost savings
Based on inputs gathered from both secondary and primary sources, the report features an informed and insightful analysis, estimating cost saving potential associated with AI-based solutions. In fact, the adoption of such technologies has the potential to save more than USD 20 billion in drug discovery by 2035.
North America and Europe are anticipated to capture over 85% of the market share, by 2035
In addition, the market in Asia Pacific is likely to grow at a relatively faster pace (25%) in the long term. Further, in 2035, the AI-based drug discovery market for oncological disorders is expected to capture the majority share (~38%) of the total market.
To request a sample copy / brochure of this report, please visit
https://www.rootsanalysis.com/reports/ai-based-drug-discovery-market.html
The financial opportunity within the AI-based drug discovery market has been analyzed across the following segments:
The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry. The report includes detailed transcripts of discussions held with the following experts:
The research includes profiles of key players (listed below); each profile features a brief overview of the company, details related to its AI-based drug discovery technologies, recent developments and an informed future outlook.
For additional details, please visit
https://www.rootsanalysis.com/reports/ai-based-drug-discovery-market.html or email sales@rootsanalysis.com
You may also be interested in the following:
Contact:
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Gaurav.chaudhary@rootsanalysis.com
MEDIA CITATIONS
We are your partners with no equity
We fit in your budget
We love what we do
Chance to prove ourselves
Best in class quality of work
Most trusted consulting partner in the industry
SUBSCRIBE TO INDUSTRY UPDATES
.png)
